Development of fullerene derivatives as novel lead compounds for medicine
Project Information
| Principal Investigator | Tadahiko Mashino |
| Institution | Kyoritsu University of Pharmacy |
| Project URL | View |
| Relevance to Implications | Some |
| Class of Nanomaterial | Engineered Nanomaterials |
| Impact Sector | Human Health |
| Broad Research Categories |
Hazard Response Characterization |
| NNI identifier |
Funding Information
| Country | Japan |
| Anticipated Total Funding | $505,669.00 |
| Annual Funding | $38,897.62 |
| Funding Source | Ministry of Education, Culture, Sports, Science and Technology (MEXT) |
| Funding Mechanism | Extramural |
| Funding Sector | Government |
| Start Year | 1996 |
| Anticipated End Year | 2009 |
Abstract/Summary
Fullerene and its derivatives show interesting biological activities based on their unique physical properties and chemical reactivity. We intend to develop fullerene derivatives as a new type of lead compound to be used as medicine and have reported that the anionic fullerene derivatives show antioxidant activities, the cationic derivatives have antibacterial and antiproliferative activities, and amino-acid types of fullerene derivatives have Human immunodeficiency virus-reverse transcriptase inhibition activities. Our data suggest that the fullerene derivatives are promising novel lead compounds for anti-neurodegenerative disease, anti-cancer, anti-bacterial, and anti-HIV drug.
